Tumor Necrosis Factor Inhibitor Monotherapy Versus Combination Therapy for the Treatment of Psoriatic Arthritis: Combined Analysis of European Biologics Databases
The Journal of Rheumatology2020Vol. 48(1), pp. 48–57
Citations Over TimeTop 19% of 2020 papers
Matthew L. Thomas, Gavin Shaddick, Rachel Charlton, Charlotte Cavill, Richard Holland, Florenzo Iannone, Giovanni Lapadula, S. Lopriore, Jakub Závada, Michal Uher, Karel Pavelká, Lenka Szczuková, Prodromos Sidiropoulos, Irini Flouri, Alexandros A. Drosos, Burkhard Möller, Michael J. Nissen, Rüdiger Müller, Almut Scherer, Neil McHugh, Alison Nightingale
Abstract
Combination therapy of a TNFi with a csDMARD does not appear to affect improvement of disease activity or HAQ versus TNFi monotherapy, but it may improve TNFi drug survival.
Related Papers
- → Prevalence of Psoriasis and Psoriatic Arthritis and Patient Perceptions of Severity in Sweden, Norway and Denmark: Results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis(2018)33 cited
- → Cardiovascular Comorbidities of Psoriasis and Psoriatic Arthritis: A Report from the GRAPPA 2012 Annual Meeting(2013)25 cited
- → Risk factors and predictors of psoriatic arthritis in patients with psoriasis(2013)11 cited
- → Periods till psoriatic arthritis onset and diagnosis in Russian patients with moderate to severe psoriasis (according to psoriasis patient registry)(2023)1 cited
- → Influence of age of onset of psoriasis on prevalence and clinical characteristics of psoriatic arthritis (according to the registry of patients with psoriasis)(2022)